leadf
logo-loader
viewPoolbeg Pharma PLC
(
AIM:POLB
)

Poolbeg Pharma enters AIM with plans to develop treatment for influenza big pharma partnership

Poolbeg Pharma PLC (LON:POLB) is analysed by Proactive Research Analyst Robin Davison on its first day of dealings on AIM after being spun out from Open Orphan PLC (LON:ORPH).

The firm has come to the market with an oversubscribed £25mln IPO.

As Davidson explains, Poolbeg plans to develop a potential treatment for influenza and is aiming for a near-term partnership with big pharma.

Click here to read Proactive's initiation report on 'Poolbeg Pharma: Trading now underway'

Quick facts: Poolbeg Pharma PLC

Follow
AIM:POLB

Price: 10.75 GBX

Market Cap: £53.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Poolbeg Pharma Presenting at the Proactive One2One Virtual Forum - 16th...

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. Poolbeg aspires to become a “one-stop shop” for big pharma to...

1 week, 3 days ago

2 min read